文献速递主动脉外科

术中纤维蛋白原替代治疗对A型急性主动脉夹层手术结局的影响

The Impact of Intraoperative Fibrinogen Replacement Therapy on the Clinical Outcome of Surgical Therapy for Type A Acute Aortic Dissection.
PubMed 文献 · Interdiscip Cardiovasc Thorac Surg · 2026-01-01

该回顾性研究分析87例急诊手术的A型急性主动脉夹层患者,比较接受纤维蛋白原替代治疗(Group F,n=42)与未接受者(Group C,n=45)的术中及术后纤维蛋白原水平、失血量及短期和长期手术结局。结果显示FRT使术后纤维蛋白原下降幅度更小,虽术中失血更多但术后失血无差异,且不增加不良结局。

要点

  • FRT使术后纤维蛋白原下降幅度更小(LS均值差-60.1,95%CI -79.8至-40.4)。
  • FRT组术中失血更多(LS均值差-622 mL,95%CI -1037至-208),术后失血无差异。
  • FRT不增加不良结局,对CPB脱机前纤维蛋白原低于150 mg/dL者有效。

核心结论

  • 在A型急性主动脉夹层手术中,纤维蛋白原替代治疗使纤维蛋白原水平提高约71 mg/dL,实现充分止血且不增加不良结局。
  • 对脱机前纤维蛋白原低于150 mg/dL且有出血倾向的患者,纤维蛋白原浓缩物可有效减少术后失血。

研究设计与样本

  • 回顾性研究分析87例连续接受急诊手术的A型急性主动脉夹层患者。
  • 患者分为接受纤维蛋白原替代治疗组(Group F,n=42)和未接受组(Group C,n=45)。
  • 采用重复测量混合模型计算组间术中及术后纤维蛋白原水平和失血量的最小二乘均值差。
  • 评估短期手术结局(术后并发症)和长期手术结局(总生存)。

主要发现

  • 术中纤维蛋白原水平变化组间无显著差异。
  • 术后纤维蛋白原下降幅度F组更小(LS均值差-60.1;95%CI -79.8至-40.4)。
  • 术中失血F组更多(LS均值差-622 mL;95%CI -1037至-208),术后失血无差异(LS均值差-131 mL;95%CI -547至286)。
  • 尽管F组重症比例更高,术后并发症率差异约10%。
  • 1个月生存率差异4.9%,1年生存率差异19.5%。

关键数值与推荐

  • 纤维蛋白原替代治疗使纤维蛋白原水平提高约71 mg/dL。
  • 对脱机前纤维蛋白原低于150 mg/dL且有出血倾向的患者,纤维蛋白原浓缩物可有效减少术后失血。

临床怎么用

  • 对于A型急性主动脉夹层手术患者,可考虑使用纤维蛋白原浓缩物进行替代治疗以纠正低纤维蛋白原血症。
  • 尤其对脱机前纤维蛋白原低于150 mg/dL且有出血倾向的患者,纤维蛋白原浓缩物有助于减少术后失血。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Fibrinogen replacement therapy (FRT) using fibrinogen concentrate (FC) may rapidly correct hypofibrinogenaemia; however, its clinical impact remains unclear, and this retrospective study aimed to evaluate the safety and efficacy of FC in surgically treated acute type A aortic dissection (ATAAD) patients. METHODS: A retrospective study analysed 87 consecutive ATAAD patients who underwent emergency surgery. Patients were included in 2 groups: those who received FRT (Group F, n = 42) and those who did not (Group C, n = 45). Using a mixed model for repeated measures, we calculated the least squares (LS) mean differences between groups for intraoperative and postoperative fibrinogen levels and blood loss using the LS method. We also evaluated short-term surgical outcomes (postoperative complications) and long-term surgical outcomes (overall survival) for each group. RESULTS: The change in fibrinogen levels during surgery did not differ significantly between groups. Postoperatively, however, the decrease in fibrinogen was smaller in the F group (LSMeans difference: -60.1; 95% confidence interval [CI]: -79.8, -40.4). Intraoperative blood loss was greater in the F group (LSMeans difference: -622 mL; 95% CI, -1037, -208), but no difference was observed in postoperative blood loss (LSMeans difference: -131 mL; 95% CI, -547, 286). Despite a higher proportion of severe cases in the F group, the difference in postoperative complication rates was approximately 10%. The difference in 1-month survival rate was 4.9%, and the difference in 1-year survival rate was 19.5%. CONCLUSIONS: In the surgical treatment of ATAAD, FRT increases fibrinogen levels by approximately 71 mg/dL, achieving adequate haemostasis without increasing adverse outcomes. Additionally, FC is effective in reducing postoperative blood loss in patients with a bleeding tendency whose fibrinogen level is below 150 mg/dL before weaning from cardiopulmonary bypass.

来源:Interdiscip Cardiovasc Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Takehara M, Shimamoto T, Sakamoto K, et al. The Impact of Intraoperative Fibrinogen Replacement Therapy on the Clinical Outcome of Surgical Therapy for Type A Acute Aortic Dissection. Interdiscip Cardiovasc Thorac Surg. 2026. PMID: 41782352. doi:10.1093/icvts/ivag075

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。